Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Intravesical MK-3120 in High-Risk NMIBC (BCG-Naïve or BCG-Exposed)
2025-520467-40-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, single-arm trial of MK-3120 in bladder cancer, sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience a Dose-limiting Toxicity (DLT), Number of Participants Who Experience One or More Adverse Events (AEs) and 1 more. Planned start Mar 2026; status: authorised.
02
Drugs
MK-3120
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2025-520467-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520467-40-00.